Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway.

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

The FDA approved Opdualag on the strength of the phase 2/3 RELATIVITY-047 trial in unresectable or metastatic melanoma, which demonstrated that patients on the combination drug had a median ...

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s ...

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...

Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...